To get a sense of who is truly in control of SAB Biotherapeutics, Inc. (NASDAQ:SABS), it is important to understand the ownership structure of the business. We can see that individual investors own ...

SAB Biotherapeutics, Inc. (SABS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus ...

Multiple analysts have issued price targets for $SABS recently. We have seen 3 analysts offer price targets for $SABS in the last 6 months, with a median target of $9 ...

SAB Biotherapeutics Inc. Annual stock financials by MarketWatch. View the latest SABS financial statements, income statements and financial ratios.

The latest price target for SAB Biotherapeutics (NASDAQ:SABS) was reported by Chardan Capital on September 19, 2025. The analyst firm set a price target for $12.00 expecting SABS to rise to within 12 ...

In a challenging market environment, Big Cypress Acquisition Corp. (SABS) stock has hit a 52-week low, trading at $2.12. While the company has faced headwinds over the past year with a 27% decline, ...

Shares of SAB Biotherapeutics SABS plunged almost 40% on Wednesday after SABS announced discontinuing enrollment in the phase III ACTIV-2 study, which is evaluating its investigational antibody ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.